PT-141 Wholesale
Bremelanotide Bulk Supply
The only research peptide that is also the active ingredient in an FDA-approved sexual health drug. PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and selective MC3R/MC4R melanocortin agonist — it initiates sexual arousal via central hypothalamic pathways, distinct from every other sexual health compound on the market. Research-grade ≥98% HPLC purity, full COA, high repeat-purchase from clinics.
What Is PT-141 (Bremelanotide)? The Central Melanocortin Agonist
PT-141, generically known as bremelanotide, is a synthetic cyclic heptapeptide derived from Melanotan II. It is a selective agonist of melanocortin receptor subtypes MC3R and MC4R, acting centrally in the hypothalamus — specifically the paraventricular nucleus (PVN) and ventromedial hypothalamus (VMH) — to initiate neural arousal signaling through downstream dopaminergic, oxytocinergic, and noradrenergic pathways.
PT-141 was approved by the FDA in June 2019 under the brand name Vyleesi® for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the only research peptide in the wholesale catalog that is simultaneously the active ingredient of an FDA-approved pharmaceutical. This regulatory history gives PT-141 an unusually well-characterized clinical safety and pharmacokinetic profile, with published Phase 2 and Phase 3 human trial data available across multiple peer-reviewed journals.
For wholesale buyers, PT-141 is the highest transactional-intent keyword in the sexual health peptide category — 50,000+ monthly searches with buyers already past the research phase and actively seeking supply. Its repeat-purchase rate from sexual health clinics, men’s health practices, and research institutions makes it one of the most reliable B2B SKUs in the specialty peptide catalog.
Central Hypothalamic Action
PT-141 activates MC3R and MC4R in the hypothalamus — not peripheral vascular receptors. This central mechanism initiates sexual arousal through neural pathways involving dopamine, oxytocin, and norepinephrine without requiring prior sexual stimulation. This is the defining pharmacological distinction from all existing PDE5 inhibitor therapies.
FDA-Referenced Compound
Bremelanotide (PT-141) is the active ingredient in Vyleesi® — FDA-approved June 2019 for HSDD in premenopausal women. This clinical history provides wholesale buyers with an unusually robust published evidence base: Phase 1, 2, and 3 trial data, pharmacokinetic profiles, and safety data from the RECONNECT pivotal trial are all publicly available in peer-reviewed journals.
Melanocortin Selectivity
PT-141 was structurally designed from Melanotan II to maximize MC4R and MC3R binding affinity while minimizing MC1R activation (which causes skin tanning/hyperpigmentation). This selectivity — MC3R/MC4R agonism with reduced MC1R activity — is the pharmacological engineering that distinguishes PT-141 from its Melanotan II predecessor.
Highest Transactional Intent
PT-141 wholesale generates 50,000+ monthly searches with the highest purchase-ready buyer profile in the sexual health peptide category. Buyers searching for PT-141 wholesale already know the compound and are actively sourcing supply — not researching what it is. This translates directly to the highest conversion rate of any sexual health research peptide in B2B wholesale.
PT-141 vs PDE5 Inhibitors — Central vs Peripheral
The most critical distinction in PT-141 research and clinical application is the mechanism difference from PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis). PT-141 and PDE5 inhibitors act on completely different pathways, at different anatomical locations, through different molecular mechanisms. They are not competing alternatives — they are pharmacologically complementary compounds addressing different aspects of sexual function.
Central Mechanism — Neural Arousal Initiation
- Acts in the hypothalamus (PVN, VMH) — central nervous system
- Activates MC3R and MC4R via cAMP signaling
- Triggers dopamine, oxytocin, norepinephrine release
- Initiates desire and arousal — does not require prior stimulation
- Onset: 45–90 minutes post-subcutaneous administration
- Duration: 6–8 hours
- Active in both men and women (MC4R expressed in both)
- Effective even when hormones are normal
Peripheral Mechanism — Vascular Enhancement
- Acts in peripheral vascular smooth muscle — not CNS
- Inhibits phosphodiesterase-5 → ↑ cGMP → smooth muscle relaxation
- Increases blood flow to genitalia
- Requires existing sexual arousal to work — enhances response, not initiation
- Does not address desire disorders
- No approved indication for women
- Contraindicated with nitrates (hypotension risk)
PT-141 Neural Pathway — From MC4R to Arousal
The cascade from PT-141 receptor binding to the physiological arousal response:
The Five Melanocortin Receptors — Why MC3R and MC4R Matter
The melanocortin receptor family (MC1R–MC5R) regulates diverse physiological functions including pigmentation, energy homeostasis, immune function, and sexual behavior. PT-141’s therapeutic activity and research value derive specifically from its MC3R and MC4R selectivity — and the intentional avoidance of MC1R binding (tanning) that was the limitation of its predecessor Melanotan II.
| Receptor | Primary Location | Primary Function | PT-141 Binding |
|---|---|---|---|
| MC1R | Melanocytes, skin | Melanin production, skin pigmentation | Low (intentionally minimized) |
| MC2R | Adrenal cortex | ACTH signaling, cortisol production | No binding |
| MC3R | Hypothalamus, limbic system | Energy balance, sexual behavior, anorexigenic signaling | ✓ Primary target |
| MC4R | Hypothalamus (PVN, VMH), brainstem | Sexual arousal initiation, energy homeostasis, erectile function | ✓ Primary target |
| MC5R | Exocrine glands, immune cells | Exocrine secretion, immune modulation | Minimal |
MC4R is the primary receptor mediating PT-141’s arousal effects — it is expressed in hypothalamic circuits governing both sexual motivation and erectile function. MC4R knockout studies in animal models demonstrate complete abrogation of the sexual arousal response to melanocortin agonists, confirming MC4R as the critical mediator. MC3R co-activation contributes to the limbic and reward pathway amplification of the arousal signal.
PT-141 Wholesale — Full Specifications
Chemical & Molecular Data
| Generic Name | Bremelanotide |
| Brand Name | Vyleesi® (FDA-approved drug) |
| Peptide Type | Cyclic heptapeptide |
| Sequence | Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-OH |
| Molecular Weight | 1,025.18 Da |
| Molecular Formula | C₅₀H₆₈N₁₄O₁₀ |
| CAS Number | 189691-06-3 |
| Derived From | Melanotan II (structural analog) |
Quality & Purity Standards
| HPLC Purity | ≥98% (batch tested) |
| Identity | Mass spec confirmed (MW 1,025.18 Da) |
| Cyclic Structure | Confirmed on COA |
| Endotoxin | <1 EU/mg (LAL method) |
| Sterility | Sterile-filtered, aseptic fill |
| Water Content | <5% (Karl Fischer) |
| Storage | -20°C · 24+ months lyophilized |
| Post-reconstitution | 4°C · use within 28 days |
PT-141 Wholesale Price — Volume Tiers 2026
PT-141 at $28–$33 per 10mg vial is one of the most competitively priced specialty peptides in the sexual health wholesale catalog. High repeat-purchase rates from clinics make volume pricing arrangements particularly valuable for consistent buyers.
| Quantity | Total Price | Per Vial | Per mg | Availability |
|---|---|---|---|---|
| PT-141 10mg × 1 | $28 | $28 | $2.80 / mg | ✓ In Stock |
| PT-141 10mg × 10CLINIC PACK | $250 | $25 | $2.50 / mg | ✓ In Stock |
| PT-141 10mg × 25 | $575 | $23 | $2.30 / mg | ✓ In Stock |
| PT-141 10mg × 50 | $1,050 | $21 | $2.10 / mg | ✓ In Stock |
| PT-141 10mg × 100+ | Contact | Custom | Custom rate | ✓ In Stock |
PT-141 in Peer-Reviewed Research — The Clinical Evidence Base
PT-141 has one of the strongest clinical research bases of any research peptide in wholesale supply — the direct result of its FDA approval pathway. The following summarizes the published clinical and preclinical research record.
RECONNECT Phase 3 Trial — The Pivotal FDA Approval Study
The RECONNECT trial (Kingsberg et al., 2019, Journal of Sexual Medicine) was the pivotal Phase 3 study supporting FDA approval of bremelanotide (PT-141) for HSDD in premenopausal women. The randomized, double-blind, placebo-controlled trial demonstrated statistically significant improvements in satisfying sexual events and desire scores. The approved dose of 1.75mg subcutaneous was established through this trial. This Phase 3 human trial data is publicly available and gives PT-141 an evidence base unprecedented among research peptides.
Kingsberg SA et al., Journal of Sexual Medicine, 2019; RECONNECT trial data
Male Erectile Function Research
Early clinical research by Diamond et al. and Rosen et al. (2004, International Journal of Impotence Research) evaluated subcutaneous and intranasal PT-141 in men with mild-to-moderate erectile dysfunction, including those with inadequate response to sildenafil. These studies established the central (non-vascular) mechanism of PT-141 in men and its potential complementary role to PDE5 inhibitors — a research area of ongoing interest given the distinct pharmacological pathways involved.
Diamond LE et al., Int J Impotence Research, 2004; Rosen RC et al., Int J Impotence Research, 2004
Female Sexual Arousal Disorder Research
Diamond et al. (2006, Journal of Sexual Medicine) conducted a double-blind, placebo-controlled study of PT-141 in premenopausal women with female sexual arousal disorder (FSAD), demonstrating significant subjective arousal improvements. This study established PT-141’s efficacy in women with arousal (not just desire) disorders and contributed to the expanded understanding of melanocortin receptor function in female sexual response — an area where pharmacological treatment options were extremely limited prior to this research.
Diamond LE et al., Journal of Sexual Medicine, 2006
Melanocortin System & Sexual Behavior Research
Beyond clinical applications, PT-141 serves as a valuable pharmacological tool in basic neuroscience research studying the melanocortin system’s role in hypothalamic circuits governing sexual motivation, reward, and pair-bonding behavior. Its selective MC3R/MC4R profile makes it the preferred melanocortin agonist for receptor-specific CNS research. Published studies have used PT-141 to map MC4R expression in limbic structures and study melanocortin-dopamine pathway interactions in preclinical models.
Multiple publications in Endocrinology, Neuroendocrinology, and Journal of Neuroscience
PT-141 Wholesale Quality Standards
PT-141 is a cyclic peptide — its bioactivity depends on the intramolecular lactam bridge between the Asp and Lys residues forming the cyclic structure. Standard HPLC purity testing must be supplemented with cyclic structure confirmation, as a linear (non-cyclized) synthesis error can produce a compound with the correct mass and apparent purity but no MC4R binding activity.
Full COA Per Lot
Every batch COA available pre-purchase. HPLC purity, mass spec identity, cyclic structure confirmation.
Cyclic Structure Verified
PT-141’s lactam bridge (Asp-Lys cyclization) confirmed on COA — the key quality check most suppliers skip.
HPLC + Mass Spec
Purity ≥98% by HPLC. MW 1,025.18 Da confirmed by mass spectrometry per batch.
Endotoxin + Sterility
LAL endotoxin <1 EU/mg. Sterile-filtered, aseptic fill confirmed.
Cold-Chain Shipping
Ships cold-chain. -20°C stable 24+ months lyophilized. Once reconstituted: 28 days at 4°C.
48h Fulfillment
In-stock orders ship within 48 business hours with cold-chain manifest.
Who Buys PT-141 Wholesale
PT-141’s high repeat-purchase rate is driven by consistent institutional demand from sexual health and men’s health practices. Not available to the general public.
Sexual Health Clinics
The primary wholesale buyer. Consistent PT-141 protocols drive predictable monthly ordering cycles and the highest repeat-purchase rate of any sexual health peptide SKU.
Men’s Health Practices
Men’s health and urology practices studying PT-141’s central mechanism for erectile dysfunction research — particularly in PDE5 inhibitor non-responder populations.
Women’s Health & HSDD Research
Gynecological and women’s health practices studying PT-141 in the HSDD indication context established by its FDA approval in Vyleesi®.
Research Institutions
Neuroscience and endocrinology labs using PT-141 as a pharmacological tool to study MC3R/MC4R receptor biology, hypothalamic circuits, and melanocortin-dopamine pathway interactions.
Longevity & Integrative Practices
Comprehensive longevity and integrative medicine practices incorporating sexual health research protocols alongside metabolic and hormonal research programs.
Compounding Pharmacies
503A/503B pharmacies with PT-141 compounding programs requiring research-grade bulk ingredient supply with full regulatory traceability documentation.
PT-141 Wholesale — Frequently Asked Questions
Research Use Only: PT-141 (bremelanotide) and all products on this page are sold strictly for in vitro research and laboratory use only. PT-141 is the active ingredient of Vyleesi®, an FDA-approved drug product. This research-grade material is not the approved drug product and has not been independently evaluated by the FDA as a research compound. Not intended for human or veterinary therapeutic use except as part of a licensed clinical or research program. Buyers are solely responsible for determining the legality of this compound in their jurisdiction and for compliance with all applicable federal, state, and local laws. By purchasing, you confirm you are a licensed researcher, qualified medical professional, or institutional buyer acting within the scope of a legitimate research or clinical program.
Reviews
There are no reviews yet.